Abstract
Low-density lipoprotein (LDL) apheresis has been used increasingly in clinical practice for the treatment of renal diseases with nephrotic syndrome (NS), specifically focal segmental glomerulosclerosis (FSGS). Persistent hyperlipidemia for prolonged periods is nephrotoxic and leads to chronic progressive glomerular and tubulointerstitial injury. Effective management of hyperlipidemia with HMG-CoA reductase inhibitors or LDL apheresis in drug-resistant NS patients may prevent the progression of renal disease and, in some patients, resolution of NS symptoms. Available literature reveals beneficial effects of LDL apheresis for NS refractory to drug therapy. Here we update on the current understanding of lipid nephrotoxicity and application of LDL apheresis to prevent progression of renal diseases.
Similar content being viewed by others
References
Lupien PJ, Moorjani S, Awad J (1976) A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1:1261–1265
Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2:1005–1007
Thompson GR (2003) LDL apheresis. Atherosclerosis 167:1–13
Kobayashi S (2008) Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9–15
Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14:57–70
Julius U (2018) Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis. https://doi.org/10.3390/jcdd5020027
Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T (2015) Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol 19:379–386
Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309–1311
Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667–672
Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K (2003) Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46:843–851
Li C, Lim SW, Choi BS, Lee SH, Cha JH, Kim IS, Kim J, Yang CW (2005) Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25:611–620
Shibata S, Nagase M, Fujita T (2006) Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17:754–764
Cormack-Aboud FC, Brinkkoetter PT, Pippin JW, Shankland SJ, Durvasula RV (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404–412
Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H (2002) Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17:798–802
Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728–734
Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016
Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L (2013) Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev:Cd005425. https://doi.org/10.1002/14651858.CD005425.pub
Muso E (2014) Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 18:286–290
Tojo K, Sakai S, Miyahara T (1988) Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai shi 30:1153–1160
Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, Fukazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121–1130
Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T (1998) LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 50:1–7
Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S (1994) Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial T ransplant 9:257–264
Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y (2001) Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408–415
Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y (1999) Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl 71:S122–S125
Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T (2007) Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 67:341–344
Bobulescu IA (2010) Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 19:393–402
Ruan XZ, Varghese Z, Moorhead JF (2009) An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5:713–721
Balson KR, Niall JF, Best JD (1996) Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia. J Intern Med 240:157–159
Jennette JC, Falk RJ (1990) Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis 16:432–437
Magil AB, Cohen AH (1989) Monocytes and focal glomerulosclerosis. LabInvest 61:404–409
Hovig T, Blomhoff JP, Holme R, Flatmark A, Gjone E (1978) Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidney of patients with hepatorenal syndrome. Lab Investig 38:540–549
Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13:223–235
Druilhet RE, Overturf ML, Kirkendall WM (1978) Cortical and medullary lipids of normal and nephrosclerotic human kidney. Int J BioChemiPhysics 9:729–734
Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK (2006) Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 47:539–548
Johnson AC, Stahl A, Zager RA (2005) Triglyceride accumulation in injured renal tubular cells: alterations in both synthetic and catabolic pathways. Kidney Int 67:2196–2209
Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100:3077–3082
Koyama K, Chen G, Lee Y, Unger RH (1997) Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Phys 273:E708–E713
Feldkamp T, Weinberg JM, Horbelt M, Von Kropff C, Witzke O, Nurnberger J, Kribben A (2009) Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation. Nephrol Dial Transplant 24:43–51
Weinberg JM (2006) Lipotoxicity. Kidney Int 70:1560–1566
Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM (2006) Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-reoxygenation. Am J Phys Renal Phys 290:F465–F477
Schaffer JE (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14:281–287
Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69:596–604
Mitsnefes M, Kartal J, Khoury P, Daniels S (2007) Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2:46–50
Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF (2012) Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 18:963–970
Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936–1947
Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, Keil A, Karpitskiy A, Hu J, Huh CJ, Cella M, Gross RW, Miner JH, Shaw AS (2015) Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest 125:2307–2316
Okamura K, Dummer P, Kopp J, Qiu L, Levi M, Faubel S, Blaine J (2013) Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One 8:e54817
Yoshikawa N, Ito H, Akamatsu R, Hazikano H, Okada S, Matsuo T (1986) Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med 110:394–398
Jovin IS, Taborski U, Muller-Berghaus G (2000) Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis. ASAIO J 46:298–300
Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS et al (1992) Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Am J Cardiol 70:1010–1016
Armstrong VW, Schuff-Werner P, Eisenhauer T, Helmhold M, Stix M, Seidel D (1994) Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp (a) levels. Chem Phys Lipids 67-68:315–321
Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65:161–168
Schettler V, Monazahian M, Wieland E, Ramadori G, Grunewald RW, Thomssen R, Muller GA (2001) Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Investig 31:154–155
Moriarty PM, Gibson CA, Shih J, Matias MS (2001) C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158:495–498
Bosch T, Lennertz A, Kordes B, Samtleben W (1999) Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Ther Apher 3:209–213
Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W (1997) LDL hemoperfusion—a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 21:1060–1065
Oto J, Suga K, Matsuura S, Kondo S, Ohnishi Y, Inui D, Imanaka H, Kagami S, Nishimura M (2009) Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis. J Anesth 23:284–287
Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M (2007) Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol 22:889–892
Hattori M, Ito K, Kawaguchi H, Tanaka T, Kubota R, Khono M (1993) Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196–198
Munoz M, Lumbreras J, Madrid A, Lara LE, Chocron S, Vilalta R, Ariceta G (2017) Complete remission of post-transplant recurrence of focal segmental glomerulosclerosis in children with the use of LDL-apheresis therapy: case report. Pediatric Transplantation. Wiley, Hoboken, p 63
Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, Aihara Y, Yokota S (2007) Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. Pediatr Nephrol 22:603–606
Tojo K, Sakai S, Miyahara T (1990) Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Prog Clin Biol Res 337:193–194
Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric N (2015) Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19:6–33
FDA (2018) Liposorber® LA-15 System FDA Executive Summary. Available from https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM601669.pdf. Accessed 20 April 2018
Sato Y, Tsunoda S, Nozue T, Pan Q, Wakasugi H, Yoshimura A (2012) Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy. Intern Med 51:2597–2602
Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E (2006) Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65:423–426
Iwahori T, Yoshida M (2000) Low-density lipoprotein apheresis can improve type AA systemic amyloidosis. Nephron 86:248–250
Shibata T, Okabe E, Sumie A, Ishii T, Tomo T, Yasumori R, Nasu M, Nomura Y (1994) A case of nephrotic syndrome due to IgA nephropathy complicated by acute renal failure and ameriolated by low density lipoprotein (LDL) apheresis. Nihon Toseki Igakkai Zasshi 27:233–236
Daimon S, Saga T, Nakayama M, Nomura Y, Chikaki H, Dan K, Koni I (2000) Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis. Nephrol Dial Transplant 15:235–238
Shiraishi N, Kitamura K, Hayata M, Ogata T, Tajiri-Okamura K, Nakayama Y, Kohda Y, Tomita K, Mukoyama M (2015) Low-density lipoprotein apheresis for proteinuria in lupus nephritis with intraglomerular foam cells containing cholesterol crystals. Am J Kidney Dis 65:490–493
Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722–732
Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T (2015) A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome. Nephron Extra 5:58–66
Tanaka A, Nakamura T, Sato E, Node K (2016) Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy. Nephrology 21:1073–1074
Stenvinkel P, Alvestrand A, Angelin B, Eriksson M (2000) LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Investig 30:866–870
Brunton C, Varghese Z, Moorhead JF (1999) Lipopheresis in the nephrotic syndrome. Kidney Int Suppl 71:S6–S9
Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T (1996) Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Nihon Jinzo Gakkai shi 38:46–51
FDA (2018) FDA Listing of CDRH Humanitarian Device Exemptions. Available from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=H170002. Accessed 20 April 2018
Sannomiya A, Murakami T, Koyama I, Nitta K, Nakajima I, Fuchinoue S (2018) Preoperative low-density lipoprotein apheresis for preventing recurrence of focal segmental glomerulosclerosis after kidney transplantation. J Transp Secur 2018:1–5
FDA (2013) A patient guide to the Liposorber LA-15 System. Available from https://www.accessdata.fda.gov/cdrh_docs/pdf12/H120005D.pdf. Accessed 20 April 2018
Blue Cross Blue Shield of North Carolina (2013) Blue Cross Blue Shield of North Carolina Corporate Medical Policy: lipid apheresis. Available from https://www.bluecrossnc.com/sites/default/files/document/attachment/services/public/pdfs/medicalpolicy/lipid_apheresis.pdf. Accessed 23 April 2018.
NIH (2014) Post approval study of Liposorber LA-15 System for the treatment of focal segmental glomerulosclerosis in children. Available from https://clinicaltrials.gov/ct2/show/NCT02235857. April 28 2018
FDA (2013) LIPOSORBER LA-15 SYSTEM operator’s manual. Available from www.accessdata.fda.gov/cdrh_docs/pdf12/H120005C.pdf April 26 2018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no conflict of interest.
Electronic supplementary material
ESM 1
(DOCX 15 kb)
Rights and permissions
About this article
Cite this article
Raina, R., Krishnappa, V. An update on LDL apheresis for nephrotic syndrome. Pediatr Nephrol 34, 1655–1669 (2019). https://doi.org/10.1007/s00467-018-4061-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-018-4061-9